These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1339 related items for PubMed ID: 17205456

  • 1. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 2. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166
    [Abstract] [Full Text] [Related]

  • 3. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 4. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.
    J Infect Dis; 2004 Nov 15; 190(10):1860-8. PubMed ID: 15499544
    [Abstract] [Full Text] [Related]

  • 5. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaïed F, Leport C, Raffi F, ANRS CO8 (APROCO/COPILOTE) Study Group.
    HIV Med; 2007 Apr 15; 8(3):156-63. PubMed ID: 17461859
    [Abstract] [Full Text] [Related]

  • 6. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 15; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.
    AIDS; 2006 Aug 01; 20(12):1613-9. PubMed ID: 16868442
    [Abstract] [Full Text] [Related]

  • 8. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 9. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS.
    AIDS; 2006 Feb 14; 20(3):371-7. PubMed ID: 16439870
    [Abstract] [Full Text] [Related]

  • 10. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 12; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 12. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR, Harrigan R, Heath K, Yip B, Brumme ZL, Harris M, Hogg RS, Montaner JS.
    J Infect Dis; 2005 Nov 15; 192(10):1787-93. PubMed ID: 16235178
    [Abstract] [Full Text] [Related]

  • 13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 14. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A, Spanish Group of Paediatric HIV Infection.
    Clin Infect Dis; 2006 Mar 15; 42(6):862-9. PubMed ID: 16477566
    [Abstract] [Full Text] [Related]

  • 16. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR, Chaisson RE, Keruly J, Moore RD.
    J Infect Dis; 2003 Dec 01; 188(11):1659-65. PubMed ID: 14639536
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 18. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.
    AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087
    [Abstract] [Full Text] [Related]

  • 19. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC.
    HIV Med; 2010 Jan 11; 11(1):54-63. PubMed ID: 19659943
    [Abstract] [Full Text] [Related]

  • 20. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.
    Antivir Ther; 2010 Jan 11; 15(2):165-75. PubMed ID: 20386071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.